Giuliani N - Search Results

1

Possible targets to treat myeloma-related osteoclastogenesis.

Bolzoni M, Toscani D, Storti P, Marchica V, Costa F, Giuliani N. Bolzoni M, et al. Among authors: giuliani n. Expert Rev Hematol. 2018 Apr;11(4):325-336. doi: 10.1080/17474086.2018.1447921. Epub 2018 Mar 9. Expert Rev Hematol. 2018. PMID: 29495905 Review.

2

New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).

Giuliani N, Colla S, Rizzoli V. Giuliani N, et al. Exp Hematol. 2004 Aug;32(8):685-91. doi: 10.1016/j.exphem.2004.03.015. Exp Hematol. 2004. PMID: 15308315 Free article. Review.

3

Angiopoietin-1 and myeloma-induced angiogenesis.

Giuliani N, Colla S, Morandi F, Rizzoli V. Giuliani N, et al. Leuk Lymphoma. 2005 Jan;46(1):29-33. doi: 10.1080/1042-8190400001022. Leuk Lymphoma. 2005. PMID: 15621778 Review.

4

Angiogenic switch in multiple myeloma.

Giuliani N, Colla S, Rizzoli V. Giuliani N, et al. Hematology. 2004 Oct-Dec;9(5-6):377-81. doi: 10.1080/10245330400018524. Hematology. 2004. PMID: 15763977 Review.

5

Update on the pathogenesis of osteolysis in multiple myeloma patients.

Giuliani N, Colla S, Rizzoli V. Giuliani N, et al. Acta Biomed. 2004 Dec;75(3):143-52. Acta Biomed. 2004. PMID: 15796087 Review.

6

Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.

Giuliani N, Rizzoli V, Roodman GD. Giuliani N, et al. Blood. 2006 Dec 15;108(13):3992-6. doi: 10.1182/blood-2006-05-026112. Epub 2006 Aug 17. Blood. 2006. PMID: 16917004 Free article. Review.

7

CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.

Giuliani N, Lisignoli G, Colla S, Lazzaretti M, Storti P, Mancini C, Bonomini S, Manferdini C, Codeluppi K, Facchini A, Rizzoli V. Giuliani N, et al. Cancer Res. 2008 Aug 15;68(16):6840-50. doi: 10.1158/0008-5472.CAN-08-0402. Cancer Res. 2008. PMID: 18703490

8

Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets.

Giuliani N, Mangoni M, Rizzoli V. Giuliani N, et al. Exp Hematol. 2009 Aug;37(8):879-86. doi: 10.1016/j.exphem.2009.04.004. Epub 2009 May 14. Exp Hematol. 2009. PMID: 19446662 Free article. Review.

9

Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.

Todoerti K, Lisignoli G, Storti P, Agnelli L, Novara F, Manferdini C, Codeluppi K, Colla S, Crugnola M, Abeltino M, Bolzoni M, Sgobba V, Facchini A, Lambertenghi-Deliliers G, Zuffardi O, Rizzoli V, Neri A, Giuliani N. Todoerti K, et al. Among authors: giuliani n. Exp Hematol. 2010 Feb;38(2):141-53. doi: 10.1016/j.exphem.2009.11.009. Epub 2009 Dec 4. Exp Hematol. 2010. PMID: 19963035 Free article.

10

Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients.

Giuliani N, Lisignoli G, Novara F, Storti P, Zaffaroni N, Villa R, Sammarelli G, Agnelli L, Todoerti K, Bernardo ME, Manferdini C, Colla S, Abeltino M, Bolzoni M, Rocci A, Gabusi E, Palumbo A, Zuffardi O, Neri A, Rizzoli V. Giuliani N, et al. Leukemia. 2010 Jul;24(7):1368-70. doi: 10.1038/leu.2010.96. Epub 2010 May 20. Leukemia. 2010. PMID: 20485369 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

241 results

Search Page